UroGen Pharma is a biopharmaceutical company focused on building and commercializing solutions that treat specialty cancers and urologic diseases. Co.'s primary investigational candidates, UGN-101 and UGN-102, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer, respectively. Co.'s clinical stage pipeline also includes UGN-201, its proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer, which may include carcinoma in situ. The URGN stock yearly return is shown above.
The yearly return on the URGN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the URGN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|